DADC
RPRX icon

D.A. Davidson & Co’s Royalty Pharma RPRX Stock Holding History

D.A. Davidson & Co’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,247
Closed -$1.41M – 1581
2025
Q2 		$1.41M Buy
39,247
+1,612
+4% +$53.4K 0.01% 711
2025
Q1 		$1.17M Sell
37,635
-10,511
-22% -$333K 0.01% 716
2024
Q4 		$1.23M Buy
48,146
+2,181
+5% +$57.8K 0.01% 702
2024
Q3 		$1.3M Buy
+45,965
New +$1.27M 0.01% 683

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.A. Davidson & Co's RPRX Position: Q3 2025 in Review

D.A. Davidson & Co sold out of Royalty Pharma (RPRX) in Q3 2025, closing a stake of 39,247 shares — an estimated $1.41M sold.

D.A. Davidson & Co first reported a position in RPRX in Q3 2024 and held it in 4 quarters. The position peaked at $1.41M in Q2 2025. 487 funds tracked by Wall St. Rank hold RPRX as of Q3 2025.

  • D.A. Davidson & Co reported no remaining Royalty Pharma position as of Q3 2025 after selling out during the quarter.
  • D.A. Davidson & Co sold 39,247 Royalty Pharma shares in Q3 2025, an estimated $1.41M.
  • D.A. Davidson & Co first reported a position in Royalty Pharma in Q3 2024 and held it in 4 quarters.
  • D.A. Davidson & Co's Royalty Pharma position peaked at $1.41M in Q2 2025.
  • 487 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2025.

Based on D.A. Davidson & Co's 13F filing for Q3 2025, filed 22 Oct 2025.